Clinical trials: Advanced Lung Cancer
Non-Small Cell Lung Cancer
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
The current understanding of PR104 justifies the evaluation of PR104 with docetaxel in subjects with Non Small Cell Lung Cancer (NSCLC). These include: Aldo-keto reductase 1C3 (AKR1C3).
- Trial name
- NCT00862134
- Testing
- PR104, docetaxel, Granulocyte colony-stimulating factor
- Where
- 27 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- Proacta, Incorporated
Non Small Cell Lung Cancer
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01854034
- Testing
- AUY922
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer
Phase I/II Calcitriol in Lung Cancer
According to the Cancer Atlas, lung cancer remains the major cancer among the 10.9 million new cases of cancer diagnosed annually worldwide.
- Trial name
- NCT00794547
- Testing
- Calcitriol
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-small Cell Lung Cancer
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with…
- Trial name
- NCT03409614
- Testing
- REGN2810, REGN2810/chemo/ipi, Chemotherapy
- Where
- 133 sites in United States, Austria and 16 more
- Volunteers
- 789 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Lung
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcinoma (SCC) of the lung who have failed a prior platinum-based chemotherapy regimen will receive glembatumumab vedotin.
- Trial name
- PrE0504 (NCT02713828)
- Testing
- Phase I: Glembatumumab Vedotin, Phase II: Glembatumumab Vedotin
- Where
- 10 sites in United States
- Volunteers
- 13 people
- Sponsor
- PrECOG, LLC.
Non-small Cell Lung Cancer
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
This study is being done to evaluate the safety of the investigational study drug, selinexor when given with docetaxel to patients who have been previously treated for advanced KRAS mutant lung cancer.
- Trial name
- NCT03095612
- Testing
- Selinexor, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib. The trial is open-ended, which means patients will continue to take rociletinib until the study doctor determines it is no longer…
- Trial name
- NSCLC (NCT02147990)
- Testing
- Rociletinib
- Where
- 91 sites in United States, Australia and 10 more
- Volunteers
- 318 people
- Sponsor
- Clovis Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
This observational study will investigate the efficacy, safety, tolerability and symptom control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally advanced or metastatic NSCLC harboring…
- Trial name
- NCT02047903
- Testing
- Afatinib
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Boehringer Ingelheim
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Chemotherapy-Induced Thrombocytopenia
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung…
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer
- Trial name
- NCT00413283
- Testing
- Romiplostim, Gemcitabine, Carboplatin
- Where
- 113 sites in United States, Austria and 6 more
- Volunteers
- 63 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene.
- Trial name
- NCT00932451
- Testing
- PF-02341066
- Where
- 280 sites in United States, Australia and 20 more
- Volunteers
- 1,069 people
- Sponsor
- Pfizer
Lung Cancer
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
- Trial name
- NCT00193453
- Testing
- Gemcitabine, Docetaxel, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- SCRI Development Innovations, LLC
NSCLC, Stage IV, NSCLC Stage IIIB
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Open-label, Phase 2, single treatment arm, 3 cohorts
- Conditions
- NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC, NSCLC, Recurrent
- Trial name
- RAIN (NCT03805841)
- Testing
- tarloxotinib bromide
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- Rain Oncology Inc
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Carcinoma, Small Cell, Small Cell Lung Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
- Trial name
- NCT00298896
- Testing
- SNS-595
- Where
- 17 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Sunesis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio.
- Trial name
- INFORM (NCT00770588)
- Testing
- Gefitinib
- Where
- 14 sites in China
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Real World Data on Gi(l)Otrif® Dose Adjustment
This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label.
- Trial name
- NCT02751879
- Where
- 29 sites in United States, Austria and 11 more
- Volunteers
- 228 people
- Sponsor
- Boehringer Ingelheim